Central Institute of Mental Health
Department of Child and Adolescent Psychiatry and Psychotherapy
D-68159 Mannheim



Project leader  

Prof. Dr. Tobias Banaschewski, MD, PhD, Medical Director

Phone: +49 (0) 621/1703-4502

Fax:      +49 (0) 621/1703-4505

Email: tobias.banaschewski@zi-mannheim.de



Prof. Dr. Ralf W. Dittmann, MD, PhD    

Professor of Pediatric Psychopharmacology 

Phone: +49 (0) 621/1703-4941               

Fax:       +49 (0) 621/1703-4945  

Email:    ralf.dittmann@zi-mannheim.de


Project staff
Dr. Alexander Häge, MD
Phone: +49 (0) 621/1703-4924
Fax:       +49 (0) 621/1703-4545

Email:   alexander.haege@zi-mannheim.de

Konstantin Mechler
Phone: +49 (0) 621/1703-4924
Fax:       +49 (0) 621/1703-4945

Email:   Konstantin.mechler@zi-mannheim.de

Dr. Mahmud Ben Dau
Phone: +49 (0) 621/1703-4943
Fax:       +49 (0) 621/1703-4945

Email:   Mahmud.Ben_Dau@zi-mannheim.de

Ruth Berg, MSc, study coordinator
Phone: +49 (0) 621/1703-4941
Fax:       +49 (0) 621/1703-4545

Email:   ruth.berg@zi-mannheim.de


Description of the organization:

The Central Institute of Mental Health (CIMH) in Mannheim, Germany is an independent public foundation of the State of Baden-Württemberg associated with the University of Heidelberg and is one of Europe’s premier research institutions dedicated to mental health. It is dedicated to research in psychiatry, addiction medicine, psychosomatic medicine and psychotherapy, neuroscience, clinical psychology, medical sociology and epidemiology. The Institute has been a Collaborating Centre for Research and Training in Mental Health with the WHO since 1980. The Department of Child and Adolescent Psychiatry and Psychotherapy (CAP), headed by Prof. Tobias Banaschewski, MD, PhD, at the (CIMH), specialises in psychiatric treatment and research in neuropsychiatric disorders (e.g., ADHD, Conduct Disorders, Tourette Syndrome and Autism). Research on efficacy and safety of medication treatment for psychiatric disorders in youths is a main focus of the department’s research agenda. In the summer of 2008, the Eli Lilly Endowed Chair for Paediatric Psychopharmacology was established at CAP focusing on clinical research with psychotropic compounds in children and adolescents (Prof Ralf W. Dittmann). The CAP is equipped with 52 inpatient beds distributed in 4 units/wards plus an outpatient facility. The Department’s outpatient clinic has about 400 new child and adolescent ADHD patients per year. The clinical and research teams include a total of 18 child and adolescent psychiatrists, 12 senior psychologists and 2 post-doctoral staffs.


Previous experience:

CAP CIMH has been involved in several international collaborations including various multisite medication trials. Prof. Banaschewski has been the principle investigator in several research projects including a current registration trial for a new ADHD compound. He has also been Co-PI on a NIH sponsored project on the genetics of ADHD (International Multisite ADHD Genetics – IMAGE, R01MH62873 to Steve Faraone, P.I.). The CIMH also has extensive experience in the management and implementation of earlier EU FP projects. The CAP CIMH (R.W. Dittmann & T. Banaschewski) is also participating in the Pediatric European Risperidone Study (PERS) which will be funded by FP7 (PI: Jan Buitelaar) and is responsible for the work package ‘Risperidone in Conduct Disorder, acute trial’ (R.W.Dittmann).


Profile of staff members

Tobias Banaschewski (MD, PhD) is an expert in the neurobiology and neuropsychology of ADHD and associated child psychiatric disorders. He is currently Co-PI of the NIMH-funded International Multi-Centre ADHD Genetics Project and is a member of the Advisory Board of the European Network of Research on Hyperkinetic Disorders. He was awarded the Kramer-Pollnow-Award for research on ADHD in 2003. He is the Co-Editor of the JCPP and Member of the EUNETHYDIS Guidelines Group on diagnosis and treatment of ADHD. He is also the director of the Department of Child and Adolescent Psychiatry and Psychotherapy, CIMH, Mannheim, and a Chair at the University of Heidelberg.

Ralf W. Dittmann (MD, PhD) is a child and adolescent psychiatrist, clinical psychologist and Professor of Paediatric Psychopharmacology and also a recipient of the H. Emminghaus award. He has been responsible for more than 70 clinical trials including the role of principal investigator.

Daniel Brandeis is Professor for Developmental Clinical Neurophysiology at the Universities of Heidelberg and at Zürich, holds degrees in neurobiology and psychology, and is a recipient of the Kramer-Pollnow award. His research focuses on the developmental neuroscience of state regulation, attention, reading, ADHD and dyslexia, mainly using multimodal functional imaging with EEG-fMRI.

Manfred Laucht (PhD) is Professor of Neuropsychology at the CAP CIMH and head of the working group on neuropsychology. Furthermore, Prof. Laucht has broad research experience in epidemiology and gene-environment interactions and received the H. Emminghaus Award for his group in 2007.

Luise Poustka (MD) is a child and adolescent psychiatrist and focuses her research on various projects concerned with Pervasive Developmental Disorders (‘autism’).


Main tasks in the project:

This partner is responsible for the WP2 “Retrospective Cohort Data Acquisition”. In addition, it will contribute to patient recruitment in WP3.


The fifth ADDUCE Newsletter is now available!

Here, you can read about the finalisation of the project,

the European Medicines Agency and General Assembly meetings

and the dissemination of the results!

The fourth ADDUCE Newsletter is available!
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study

- the long-term cardiascular effects of methylphenidate use
Also, you can read about the future plans of the project!

More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before! 


Did you participate in the ADDUCE studies and are you curious about the latest news on the project?

Here you can find some information!

News for children, April 2015

News for adolescents, April 2015

News for parents, April 2015

The third ADDUCE Newsletter is available!

Read more about the ADDUCE studies:

- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
off studies
- the long-term cardiovascular effects of methylphenidate use: study design and participation

and much more in the ADDUCE Newsletter 3, March 2015


The second ADDUCE Newsletter is available!
Read more about the 2 main ADDUCE studies:

  • WP3: prospective open-label methylphenidate
    pharmacovigilance study
  • WP8: long-term cardiovascular effects of methylphenidate use

and much more in the ADDUCE Newsletter 2, February 2013


16 - 19 OCTOBER 2016:

4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care

17 & 18 APRIL 2016:

ADDUCE Consortium meeting, London - UK

28 - 31 MAY 2015:

5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland

20 & 21 APRIL 2015:

ADDUCE Consortium meeting, Salina - Italy

21 - 24 MAY 2014:

3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders

19 & 20 MAY 2014:

ADDUCE Consortium meeting, Istanbul - Turkey

3 - 6 OCTOBER 2013:

23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders

6 - 9 JUNE 2013:            

4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy

4 & 5 JUNE 2013:

ADDUCE Consortium meeting, Milan - Italy

 6 & 7 JUNE 2012:            

ADDUCE Consortium meeting, Cagliari - Italy

23 MAY 2012:

2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain